Polygenic Risk Score Analysis of Antidepressant Treatment Outcomes: A CAN-BIND-1 Study Report: Analyse des résultats du traitement antidépresseur à l’aide des scores de risque polygéniques : Rapport sur l’étude CAN-BIND-1
- 29 March 2025
- journal article
- Published by SAGE Publications in The Canadian Journal of Psychiatry
- Vol. 70 (7) , 552-564
Abstract
Objective: The genetic architecture of antidepressant response is poorly understood. This study investigated whether polygenic risk scores (PRSs) for major psychiatric disorders and a personality trait (neuroticism) are associated with antidepressant treatment outcomes. Methods: We analysed 148 participants with major depressive disorder (MDD) from the Canadian Biomarker Integration Network for Depression-1 (CAN-BIND-1) cohort. Participants initially received escitalopram (ESC) monotherapy for 8 weeks. Nonresponders at week 8 received augmentation with aripiprazole (ARI), while responders continued ESC until week 16. Primary outcomes were remission status and symptom improvement measured at weeks 8 and 16. At week 16, post-hoc stratified analyses were performed by treatment arm (ESC-only vs. ESC + ARI). Eleven PRSs derived from genome-wide association studies of psychiatric disorders (e.g., MDD and post-traumatic stress syndrome (PTSD)) and neuroticism, were analysed for associations with these outcomes using logistic and linear regression models. Results: At week 8, a higher PRS for PTSD was nominally associated with a lower probability of remission (odds ratio (OR) = 0.08 [0.014–0.42], empirical p -value = 0.017) and reduced symptom improvement (beta (standard error) = −29.15 (9.76), empirical p -value = 0.019). Similarly, a higher PRS for MDD was nominally associated with decreased remission probability (OR = 0.38 [0.18–0.78], empirical p -value = 0.044). However, none of the results survived multiple testing corrections. At week 16, the stratified analysis for the ESC-only group revealed that a higher PRS for MDD was associated with increased remission probability (empirical p- value = 0.034) and greater symptom improvement (empirical p -value = 0.02). In contrast, higher PRSs for schizophrenia (empirical p -value = 0.013) and attention-deficit hyperactivity disorder (empirical p -value = 0.032) were associated with lower symptom improvement. No significant associations were observed in the ESC + ARI group. Conclusions: These findings suggest that PRSs may influence treatment outcomes, particularly in ESC monotherapy. Replication in larger studies is needed to validate these observations.Keywords
Funding Information
- Ontario Brain Institute
- Canadian Institutes of Health Research
- Servier Canada
- Lundbeck Canada
This publication has 49 references indexed in Scilit:
- The Potential of Polygenic Risk Scores to Predict Antidepressant Treatment Response in Major Depression: A Systematic ReviewJournal of Affective Disorders, 2022
- Identifying the Common Genetic Basis of Antidepressant ResponseBiological Psychiatry Global Open Science, 2021
- Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorderProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2021
- The Genetic Links to Anxiety and Depression (GLAD) Study: Online recruitment into the largest recontactable study of depression and anxietyBehaviour Research and Therapy, 2019
- Pharmacogenetics of antidepressant response: A polygenic approachProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2017
- Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015The Lancet, 2016
- Meta-analysis of Genome-wide Association Studies for Neuroticism, and the Polygenic Association With Major Depressive DisorderJAMA Psychiatry, 2015
- The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment-resistant depressionEuropean Neuropsychopharmacology, 2015
- Contribution of Common Genetic Variants to Antidepressant ResponseBiological Psychiatry, 2013
- Common genetic liability to major depression and posttraumatic stress disorder in menJournal of Affective Disorders, 2008